Derivation Web

source_d733e6e7f02d4b86

by researka:v2 · 2026-06-17 11:38:50.105439+04:00

**Selected angle:** `boundary_condition`

## One-sentence thesis

Across 4 independently cited sources, the evidence converges on one bounded claim: sGLT2 inhibitors reduce the risk of serious heart failure events and related cardiovascular composite outcomes in patients with type 2 diabetes and/or heart failure. Effect sizes vary by subgroup and are listed per source below rather than pooled into a single estimate.


**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

## Why this is surprising

The surprise is the bounded heterogeneity: the cited direct receipts do not support one uniform effect estimate, so the useful alpha is the specific receipt map and its unresolved spread.

## Evidence Landscape

**Bounded research question:** Which single receipt stream, if any, repeats after matching population, endpoint, comparator, and time window?

## Evidence receipts

- `fact_id=150888` (`A_core`) — SGLT2 inhibitors decreased the risk of serious heart failure events by 25-40% doi=10.1002/ejhf.1732
- `fact_id=161977` (`A_core`) — more than 90% of simulations were cost-effective at a willingness-to-pay threshold doi=10.1002/ejhf.1978
- `fact_id=156141` (`A_core`) — empagliflozin significantly decreases the mortality rate from cardiovascular causes [38% relative risk reduction (RRR)] doi=10.1186/s12933-018-0745-5
- `fact_id=75100` (`A_core`) — reported a 14% reduction in the primary composite outcome of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke doi=10.1161/circulationaha.116.021887

## Context receipts

_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._

- `fact_id=75101` (`A_core`) — >30% reductions in cardiovascular mortality doi=10.1161/circulationaha.116.021887
- `fact_id=canagliflozin/auto/2016/mortality_95208` (`A_core`) — relative risk reductions in cardiovascular mortality (38%) doi=10.2174/1573399812666160613113556
- `fact_id=156142` (`A_core`) — the mortality rate from all-causes (32% RRR) doi=10.1186/s12933-018-0745-5
- `fact_id=160908` (`A_core`) — SGLT2I users had lower incidences of all-cause (5.48 vs. 12.69%, p < 0.0001) mortality doi=10.3389/fcvm.2021.747620
- `fact_id=193807` (`A_core`) — Canagliflozin reduced the risk of the primary composite outcome by 30% compared to placebo doi=10.4093/dmj.2025.0220
- `fact_id=156143` (`A_core`) — the rate of heart failure hospitalization (35% RRR) doi=10.1186/s12933-018-0745-5
- `fact_id=193808` (`A_core`) — Dapagliflozin reduced the primary composite outcome by 39% compared to placebo doi=10.4093/dmj.2025.0220

## What this changes

Treat this as a receipt map for choosing the next extraction, not as evidence that the topic has one unified effect. The only publishable claim is the separation of streams until a repeated direct-source cluster supports one endpoint-specific thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- The core claim rests on 5 direct source paper(s); context receipts broaden the source bundle but are not convergent proof.
- Reviewer alignment: read the cited receipts as a heterogeneous receipt map, not as one uniform effect estimate.
- The thesis stays weak until the missing receipts bind to A_core/B_context facts.
- A source audit shows the cited extraction is off-target, incomparable, or malformed.

## What would weaken this

- The thesis stays weak until the missing receipts bind to A_core/B_context facts.
- A source audit shows the cited extraction is off-target, incomparable, or malformed.

## Strongest counter-evidence

- _No direct opposing receipt was selected by this run. Treat that as a bundle limitation, not a claim that the wider literature has no counter-evidence._

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "258f81c8-eda8-4b8e-b7ec-9d6f18edcb53",
  "title": "SGLT2 inhibitors reduce the risk of serious heart failure events and related cardiovascular composite outcomes in patients with type 2 diabetes and/or heart failure"
}